ArticleThe British journal of dermatology2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.
Article in The British journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Involving patients and caregivers to develop items for a new patient-reported experience measure for older adults attending the emergency department. Findings from a nominal group technique study.Health expectations : an international journal of public participation in health care and health policy · 2023Pooled it
- Systematic review of international Delphi surveys for core outcome set development: representation of international patients.BMJ open · 2020Pooled it
- Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Pooled it
- Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review.Journal of the American Academy of Dermatology · 2020Pooled it
- Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.American journal of clinical dermatology · 2020Trial
- Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update.International journal of dermatology · 2026Review
- International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Quality of Life in Patients with Hidradenitis Suppurativa: A Scoping Review.Nursing reports (Pavia, Italy) · 2026Review
- Palliative and Supportive Care Needs in Advanced Hidradenitis Suppurativa: A Systematic Review.Cureus · 2026Review
- Exploring the Impact of Fatigue and Sleep Disturbance in Hidradenitis Suppurativa: Perspectives from Patients and Healthcare Professionals.Acta dermato-venereologica · 2026Review
- Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus.Journal of the American Academy of Dermatology · 2025Article
- Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.Pain and therapy · 2025Article
- Article
- Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.Dermatology and therapy · 2025Review
- Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.Dermatology and therapy · 2025Article
- Review
- Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.Dermatology and therapy · 2025Article
- Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data.Dermatology and therapy · 2025Article
- Comparing maximum and average numerical rating scale pain scores in hidradenitis suppurativa.Archives of dermatological research · 2025Article
- Moving forward in hidradenitis suppurativa lesion definitions and counts.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
backgroundThere is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence.
objectivesTo achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS.
methodsSix stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs).
resultsA total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set.
conclusionsRoutine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.